Fungicidal Power You Can Trust®

High-performance antifungal3,7

NAFTIN GEL 2% delivers the proven efficacy of an allylamine with the safety profile of vehicle3

  • A fungicidal allylamine that attacks offending microorganisms—highest efficacy observed at 6 weeks (4 weeks post last treatment)3
  • Adverse events comparable to vehicle3:
    • Application site reactions were the most common adverse reactions seen in clinical trials with NAFTIN GEL 2% (2%) vs vehicle (1%)

Harnessing the power of a fungicidal allylamine in a 2% gel3

Clinically proven to clear interdigital tinea pedis even after treatment ends3

Primary endpoint
Complete cure at week 6 (4 weeks post last treatment) with NAFTIN GEL 2%3

Bar graph of trial results.

Complete Cure (percentage of patients). Reference: 1.

Naftin Gel 2% Vehicle
Trial 1 17% 2%
Trial 2 26% 3%

Negative potassium hydroxide (KOH) preparation.

Negative dermatophyte culture.

Absent erythema, scaling, and pruritus.

Treatment Effectiveness (percentage of patients). Reference: 1.

Naftin Gel 2% Vehicle
Trial 1 54% 6%
Trial 2 51% 7%

Negative KOH preparation.

Negative dermatophyte culture.

Absent or nearly absent erythema, scaling, and pruritus.

Mycological Cure (percentage of patients). Reference: 1.

Naftin Gel 2% Vehicle
Trial 1 65% 14%
Trial 2 59% 10%

Negative KOH preparation.

Negative dermatophyte culture.

ExpandCollapseClick to expand complete Important Safety Information.Close

INDICATIONS AND USAGE: NAFTIN GEL 2% is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum in patients 12 years of age and older.


ADVERSE REACTIONS: In clinical trials with NAFTIN GEL 2%, the most common adverse reactions (2%) were application site reactions.

WARNINGS AND PRECAUTIONS: If redness or irritation develops with the use of NAFTIN GEL 2%, treatment should be discontinued.

Please click here for full Prescribing Information about NAFTIN GEL 2%.

REFERENCES: 1. Vlahovic TC. Choosing the right vehicle. Podiatr Manage. June/July 2008;209-218. 2. Data on file, Sebela Pharmaceuticals. 3. NAFTIN (naftifine hydrochloride) Gel 2% [package insert]. Roswell, GA; Sebela Pharmaceuticals; 2020. 4. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration/Center for Drug Evaluation and Research website. Accessed February 20, 2020. 5. Plaum S, Verma A, Fleischer AB, Olayinka B, Hardas B. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream or gel 2%. J Drugs Dermatol. 2013;12(9):1004-1008. 6. Stein Gold L, Parish L, Vlahovic T, Kircik L, et al. Efficacy and safety of naftifine HCL Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs Dermatol. 2013;12(8):911-918. 7. Brennan B, Leyden JJ. Overview of topical therapy for common superficial fungal infections and the role of new topical agents. J Am Acad Dermatol. 1997;36:S3-S8. 8. NAFTIN 2% Co-Pay Savings Offer. Sebela Pharmaceuticals, December 2019. 9.  Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. November 2011;10(11):1282-1288. 10. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. October 2011;10(10):1142-1147. 11. Robbins CM, Elston DM. Tinea pedis treatment & management. Medscape Web site. Updated November 19, 2015. Accessed February 22, 2016. 12. Phillips, RM, Rosen T. Topical antifungal agents. Allylamines and benzylamines. In: Wolverton, SE, ed. Comprehensive Dermatologic Drug Therapy. 3rd ed. Elsevier Inc. Ebook; 2013:460-472. 13. IQVIA. National Prescription Audit Report. March 2021.